BMO: Lilly's RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%

BMO Capital Markets analysts said the results potentially position lepodisiran as "one of the most durable assets in development to date" in the competitive Lp(a) space, where drugs are designed to lower the risk of cardiovascular events such as heart attack and stroke.